首页 > 最新文献

Revista Brasileira de Reumatologia (English Edition)最新文献

英文 中文
Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis 巴西风湿病学会关于诱导治疗anca相关血管炎的建议
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2017.06.003
Alexandre Wagner Silva de Souza , Ana Luisa Calich , Henrique de Ataíde Mariz , Manuella Lima Gomes Ochtrop , Ana Beatriz Santos Bacchiega , Gilda Aparecida Ferreira , Jozelia Rêgo , Mariana Ortega Perez , Rosa Maria Rodrigues Pereira , Wanderley Marques Bernardo , Roger Abramino Levy

The purpose of these recommendations is to guide the appropriate induction treatment of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) patients with active disease. The recommendations proposed by the Vasculopathies Committee of the Brazilian Society Rheumatology for induction therapy of AAV, including granulomatosis with polyangiitis, microscopic polyangiitis and renal-limited vasculitis, were based on systematic literature review and expert opinion. Literature review was performed using Medline (PubMed), EMBASE and Cochrane database to retrieve articles until October 2016. PRISMA guidelines were used for the systematic review and articles were assessed according to the Oxford levels of evidence. Sixteen recommendations were made regarding different aspects of induction therapy for AAV. The purpose of these recommendations is to serve as a guide for therapeutic decisions by health care professionals in the management of AAV patients presenting active disease.

这些建议的目的是指导抗中性粒细胞细胞质抗体相关血管炎(AAV)患者活动性疾病的适当诱导治疗。巴西风湿病学会血管病变委员会提出的AAV诱导治疗建议,包括肉芽肿病合并多血管炎、显微镜下多血管炎和肾限制性血管炎,是基于系统的文献综述和专家意见。使用Medline (PubMed)、EMBASE和Cochrane数据库检索至2016年10月的文献。系统评价采用PRISMA指南,文章根据牛津证据水平进行评估。针对AAV诱导治疗的不同方面提出了16条建议。这些建议的目的是作为卫生保健专业人员在管理出现活动性疾病的AAV患者时的治疗决策指南。
{"title":"Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis","authors":"Alexandre Wagner Silva de Souza ,&nbsp;Ana Luisa Calich ,&nbsp;Henrique de Ataíde Mariz ,&nbsp;Manuella Lima Gomes Ochtrop ,&nbsp;Ana Beatriz Santos Bacchiega ,&nbsp;Gilda Aparecida Ferreira ,&nbsp;Jozelia Rêgo ,&nbsp;Mariana Ortega Perez ,&nbsp;Rosa Maria Rodrigues Pereira ,&nbsp;Wanderley Marques Bernardo ,&nbsp;Roger Abramino Levy","doi":"10.1016/j.rbre.2017.06.003","DOIUrl":"10.1016/j.rbre.2017.06.003","url":null,"abstract":"<div><p>The purpose of these recommendations is to guide the appropriate induction treatment of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) patients with active disease. The recommendations proposed by the Vasculopathies Committee of the Brazilian Society Rheumatology for induction therapy of AAV, including granulomatosis with polyangiitis, microscopic polyangiitis and renal-limited vasculitis, were based on systematic literature review and expert opinion. Literature review was performed using Medline (PubMed), EMBASE and Cochrane database to retrieve articles until October 2016. PRISMA guidelines were used for the systematic review and articles were assessed according to the Oxford levels of evidence. Sixteen recommendations were made regarding different aspects of induction therapy for AAV. The purpose of these recommendations is to serve as a guide for therapeutic decisions by health care professionals in the management of AAV patients presenting active disease.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 484-496"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.06.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35272134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Contraception for adolescents with chronic rheumatic diseases 患有慢性风湿病的青少年避孕
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2016.07.016
Benito Lourenço , Katia T. Kozu , Gabriela N. Leal , Marco F. Silva , Elisabeth G.C. Fernandes , Camila M.P. França , Fernando H.C. Souza , Clovis A. Silva

Contraception is an important issue and should be a matter of concern in every medical visit of adolescent and young patients with chronic rheumatic diseases. This narrative review discusses contraception methods in adolescents with juvenile systemic lupus erythematosus (JSLE), antiphospholipid syndrome (APS), juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM). Barrier methods are safe and their use should be encouraged for all adolescents with chronic rheumatic diseases. Combined oral contraceptives (COC) are strictly prohibited for JSLE and APS patients with positive antiphospholipid antibodies. Reversible long-acting contraception can be encouraged and offered routinely to the JSLE adolescent patient and other rheumatic diseases. Progestin-only pills are safe in the majority of rheumatic diseases, although the main concern related to its use by adolescents is poor adherence due to menstrual irregularity. Depot medroxyprogesterone acetate injections every three months is a highly effective contraception strategy, although its long-term use is associated with decreased bone mineral density. COC or other combined hormonal contraceptive may be options for JIA and JDM patients. Oral levonorgestrel should be considered as an emergency contraception method for all adolescents with chronic rheumatic diseases, including patients with contraindication to COC.

避孕是一个重要的问题,应该是青少年和慢性风湿病患者每次就诊时关注的问题。本文综述了青少年系统性红斑狼疮(JSLE)、抗磷脂综合征(APS)、青少年特发性关节炎(JIA)和青少年皮肌炎(JDM)患者的避孕方法。屏障法是安全的,应鼓励所有患有慢性风湿病的青少年使用屏障法。抗磷脂抗体阳性的JSLE和APS患者严禁联合口服避孕药(COC)。可逆长效避孕可鼓励并常规提供给JSLE青少年患者和其他风湿病。仅使用黄体酮的药片对大多数风湿性疾病是安全的,尽管青少年使用黄体酮的主要问题是由于月经不规律导致依从性差。每三个月注射一次醋酸甲孕酮是一种非常有效的避孕策略,尽管长期使用会导致骨密度下降。COC或其他联合激素避孕药可能是JIA和JDM患者的选择。口服左炔诺孕酮应被视为所有患有慢性风湿病的青少年的紧急避孕方法,包括COC禁忌症患者。
{"title":"Contraception for adolescents with chronic rheumatic diseases","authors":"Benito Lourenço ,&nbsp;Katia T. Kozu ,&nbsp;Gabriela N. Leal ,&nbsp;Marco F. Silva ,&nbsp;Elisabeth G.C. Fernandes ,&nbsp;Camila M.P. França ,&nbsp;Fernando H.C. Souza ,&nbsp;Clovis A. Silva","doi":"10.1016/j.rbre.2016.07.016","DOIUrl":"10.1016/j.rbre.2016.07.016","url":null,"abstract":"<div><p>Contraception is an important issue and should be a matter of concern in every medical visit of adolescent and young patients with chronic rheumatic diseases. This narrative review discusses contraception methods in adolescents with juvenile systemic lupus erythematosus (JSLE), antiphospholipid syndrome (APS), juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM). Barrier methods are safe and their use should be encouraged for all adolescents with chronic rheumatic diseases. Combined oral contraceptives (COC) are strictly prohibited for JSLE and APS patients with positive antiphospholipid antibodies. Reversible long-acting contraception can be encouraged and offered routinely to the JSLE adolescent patient and other rheumatic diseases. Progestin-only pills are safe in the majority of rheumatic diseases, although the main concern related to its use by adolescents is poor adherence due to menstrual irregularity. Depot medroxyprogesterone acetate injections every three months is a highly effective contraception strategy, although its long-term use is associated with decreased bone mineral density. COC or other combined hormonal contraceptive may be options for JIA and JDM patients. Oral levonorgestrel should be considered as an emergency contraception method for all adolescents with chronic rheumatic diseases, including patients with contraindication to COC.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 1","pages":"Pages 73-81"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2016.07.016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55048611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 – Diagnosis and special situations 巴西风湿病学会关于基孔肯雅热诊断和治疗的建议。第1部分-诊断和特殊情况
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2017.05.006
Claudia Diniz Lopes Marques , Angela Luzia Branco Pinto Duarte , Aline Ranzolin , Andrea Tavares Dantas , Nara Gualberto Cavalcanti , Rafaela Silva Guimarães Gonçalves , Laurindo Ferreira da Rocha Junior , Lilian David de Azevedo Valadares , Ana Karla Guedes de Melo , Eutilia Andrade Medeiros Freire , Roberto Teixeira , Francisco Alves Bezerra Neto , Marta Maria das Chagas Medeiros , Jozélio Freire de Carvalho , Mario Sergio F. Santos , Regina Adalva de L. Couto Océa , Roger A. Levy , Carlos Augusto Ferreira de Andrade , Geraldo da Rocha Castelar Pinheiro , Mirhelen Mendes Abreu , Georges Christopoulos

Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2.

基孔肯雅热已成为发生流行病国家的一个相关公共卫生问题。直到2013年,美洲只发生了输入性病例,但在当年10月,加勒比圣马林岛报告了第一例病例。2014年9月在巴西确认了第一例本地病例;截至2016年流行病学第37周,已登记了236 287例基孔肯雅病毒可能感染病例,其中116 523例得到血清学确认。人类造成的环境变化、无序的城市增长和不断增加的国际旅行者被描述为造成大规模流行病出现的因素。临床特征为急性期发热和关节疼痛,约一半患者进展为慢性期(超过3个月),并伴有持续和致残疼痛。本研究的目的是为巴西基孔肯雅热的诊断和治疗制定建议。在MEDLINE、SciELO和PubMed数据库中进行文献综述,以确定推荐的决定。通过德尔菲法确定专家之间的协调程度,包括2次面对面会议和几轮在线投票。共制定了25条建议,分为3个专题组:(1)临床、实验室和影像学诊断;(二)特殊情况;(3)治疗。前两个主题在第1部分中介绍,治疗在第2部分中介绍。
{"title":"Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 – Diagnosis and special situations","authors":"Claudia Diniz Lopes Marques ,&nbsp;Angela Luzia Branco Pinto Duarte ,&nbsp;Aline Ranzolin ,&nbsp;Andrea Tavares Dantas ,&nbsp;Nara Gualberto Cavalcanti ,&nbsp;Rafaela Silva Guimarães Gonçalves ,&nbsp;Laurindo Ferreira da Rocha Junior ,&nbsp;Lilian David de Azevedo Valadares ,&nbsp;Ana Karla Guedes de Melo ,&nbsp;Eutilia Andrade Medeiros Freire ,&nbsp;Roberto Teixeira ,&nbsp;Francisco Alves Bezerra Neto ,&nbsp;Marta Maria das Chagas Medeiros ,&nbsp;Jozélio Freire de Carvalho ,&nbsp;Mario Sergio F. Santos ,&nbsp;Regina Adalva de L. Couto Océa ,&nbsp;Roger A. Levy ,&nbsp;Carlos Augusto Ferreira de Andrade ,&nbsp;Geraldo da Rocha Castelar Pinheiro ,&nbsp;Mirhelen Mendes Abreu ,&nbsp;Georges Christopoulos","doi":"10.1016/j.rbre.2017.05.006","DOIUrl":"10.1016/j.rbre.2017.05.006","url":null,"abstract":"<div><p>Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 421-437"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.05.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35205770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
Health related quality of life in Turkish polio survivors: impact of post-polio on the health related quality of life in terms of functional status, severity of pain, fatigue, and social, and emotional functioning 土耳其脊髓灰质炎幸存者的健康相关生活质量:脊髓灰质炎后对功能状态、疼痛严重程度、疲劳以及社交和情感功能方面的健康相关生活质量的影响
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2014.12.006
Yesim Garip , Filiz Eser , Hatice Bodur , Bedriye Baskan , Filiz Sivas , Ozlem Yilmaz

Objective

To determine the impact of postpolio-syndrome on quality of life in polio survivors.

Methods

Forty polio survivors were included in the study. Twenty-one patients fulfilling the Halstead's postpolio-syndrome criteria participated in postpolio-syndrome group. The remaining nineteen patients formed non-postpolio-syndrome group. Control group was composed of forty healthy subjects. Quality of life was evaluated by Nottingham Health Profile, depression by Beck Depression Scale and fatigue by Fatigue Symptom Inventory. Isometric muscle strength was measured by manual muscle testing.

Results

Total manual muscle testing score was 26.19 ± 13.24 (median: 29) in postpolio-syndrome group and 30.08 ± 8.9 (median: 32) in non-postpolio-syndrome group. Total manual muscle testing scores of non-postpolio-syndrome group were significantly higher than that of postpolio-syndrome group. Patients with postpolio-syndrome reported significantly higher levels of fatigue and reduced quality of life in terms of physical mobility, pain and energy when compared with patients without postpolio-syndrome and control group. It was not reported a statistically significant difference in social and emotional functioning and sleep quality between postpolio-syndrome, non-postpolio-syndrome and control groups. Also it was not found any statistically significant difference in Beck Depression Scale scores among the groups.

Conclusions

Postpolio-syndrome has a negative impact on quality of life in terms of functional status, severity of pain and energy. The identification, early recognition and rehabilitation of postpolio-syndrome patients may result in an improvement in their quality of life.

目的探讨脊髓灰质炎后综合征对幸存者生活质量的影响。方法选取40例脊髓灰质炎幸存者作为研究对象。21例符合Halstead脊髓灰质炎后综合征标准的患者参加脊髓灰质炎后综合征组。其余19例为非脊髓灰质炎后综合征组。对照组由40名健康受试者组成。生活质量采用诺丁汉健康量表,抑郁采用贝克抑郁量表,疲劳采用疲劳症状量表。等长肌力采用手工肌力测试法测定。结果脊髓灰质炎后综合征组手部肌肉测试总分为26.19±13.24分(中位数:29),非脊髓灰质炎后综合征组手部肌肉测试总分为30.08±8.9分(中位数:32)。非脊髓灰质炎后综合征组手部肌肉测试总分显著高于脊髓灰质炎后综合征组。与没有脊髓灰质炎后综合征的患者和对照组相比,脊髓灰质炎后综合征患者报告的疲劳程度明显更高,在身体活动能力、疼痛和精力方面的生活质量下降。在脊髓灰质炎后综合症、非脊髓灰质炎后综合症和对照组之间,在社交和情感功能以及睡眠质量方面没有统计学上的显著差异。各组间贝克抑郁量表得分也无统计学差异。结论脊髓灰质炎综合征在功能状态、疼痛程度和精力方面对生活质量有负面影响。脊髓灰质炎后综合征患者的识别、早期识别和康复可能会改善其生活质量。
{"title":"Health related quality of life in Turkish polio survivors: impact of post-polio on the health related quality of life in terms of functional status, severity of pain, fatigue, and social, and emotional functioning","authors":"Yesim Garip ,&nbsp;Filiz Eser ,&nbsp;Hatice Bodur ,&nbsp;Bedriye Baskan ,&nbsp;Filiz Sivas ,&nbsp;Ozlem Yilmaz","doi":"10.1016/j.rbre.2014.12.006","DOIUrl":"10.1016/j.rbre.2014.12.006","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the impact of postpolio-syndrome on quality of life in polio survivors.</p></div><div><h3>Methods</h3><p>Forty polio survivors were included in the study. Twenty-one patients fulfilling the Halstead's postpolio-syndrome criteria participated in postpolio-syndrome group. The remaining nineteen patients formed non-postpolio-syndrome group. Control group was composed of forty healthy subjects. Quality of life was evaluated by Nottingham Health Profile, depression by Beck Depression Scale and fatigue by Fatigue Symptom Inventory. Isometric muscle strength was measured by manual muscle testing.</p></div><div><h3>Results</h3><p>Total manual muscle testing score was 26.19<!--> <!-->±<!--> <!-->13.24 (median: 29) in postpolio-syndrome group and 30.08<!--> <!-->±<!--> <!-->8.9 (median: 32) in non-postpolio-syndrome group. Total manual muscle testing scores of non-postpolio-syndrome group were significantly higher than that of postpolio-syndrome group. Patients with postpolio-syndrome reported significantly higher levels of fatigue and reduced quality of life in terms of physical mobility, pain and energy when compared with patients without postpolio-syndrome and control group. It was not reported a statistically significant difference in social and emotional functioning and sleep quality between postpolio-syndrome, non-postpolio-syndrome and control groups. Also it was not found any statistically significant difference in Beck Depression Scale scores among the groups.</p></div><div><h3>Conclusions</h3><p>Postpolio-syndrome has a negative impact on quality of life in terms of functional status, severity of pain and energy. The identification, early recognition and rehabilitation of postpolio-syndrome patients may result in an improvement in their quality of life.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 1","pages":"Pages 1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2014.12.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55048067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas – BiobadaBrasil) 巴西使用TNF阻滞剂的类风湿关节炎患者的结核病发病率:来自巴西风湿病生物疗法登记处(Registro Brasileiro de monitora<s:1> o de Terapias Biológicas - BiobadaBrasil)的数据
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2017.05.005
Claudia Leiko Yonekura , Rene Donizeti Ribeiro Oliveira , David C. Titton , Roberto Ranza , Aline Ranzolin , André L. Hayata , Ângela Duarte , Inês G. Silveira , Hellen M. da S. de Carvalho , Júlio C. Bertacini de Moraes , Mirhelen Mendes de Abreu , Valéria Valim , Washington Bianchi , Claiton Viegas Brenol , Ivanio A. Pereira , Izaias Costa , José C. Macieira , José R.S. Miranda , Luiz S. Guedes-Barbosa , Manoel B. Bertolo , Paulo Louzada-Junior

Objectives

To assess the incidence of tuberculosis and to screen for latent tuberculosis infection among Brazilians with rheumatoid arthritis using biologics in clinical practice.

Patients and methods

This cohort study used data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas – BiobadaBrasil), from 01/2009 to 05/2013, encompassing 1552 treatments, including 415 with only synthetic disease-modifying anti-rheumatic drugs, 942 synthetic DMARDs combined with anti-tumor necrosis factor (etanercept, infliximab, adalimumab) and 195 synthetic DMARDs combined with other biologics (abatacept, rituximab and tocilizumab). The occurrence of tuberculosis and the drug exposure time were assessed, and screening for tuberculosis was performed. Statistical analysis: Unpaired t-test and Fisher's two-tailed test; p < 0.05.

Results

The exposure times were 981 patient-years in the controls, 1744 patient-years in the anti-TNF group (adalimumab = 676, infliximab = 547 and etanercept = 521 patient-years) and 336 patient-years in the other biologics group. The incidence rates of tuberculosis were 1.01/1000 patient-years in the controls and 2.87 patient-years among anti-TNF users (adalimumab = 4.43/1000 patient-years; etanercept = 1.92/1000 patient-years and infliximab = 1.82/1000 patient-years). No cases of tuberculosis occurred in the other biologics group. The mean drug exposure time until the occurrence of tuberculosis was 27(11) months for the anti-TNF group.

Conclusions

The incidence of tuberculosis was higher among users of synthetic DMARDs and anti-TNF than among users of synthetic DMARDs and synthetic DMARDs and non-anti-TNF biologics and also occurred later, suggesting infection during treatment and no screening failure.

目的评估巴西类风湿关节炎患者的结核病发病率,并在临床应用生物制剂筛查潜伏性结核病感染。患者和方法该队列研究使用了2009年1月至2013年5月巴西风湿病生物疗法登记处(Registro Brasileiro de monitora o de Terapias Biológicas - BiobadaBrasil)的数据,包括1552种治疗方法,其中415种仅使用合成疾病改善抗风湿药,942种合成dmard联合抗肿瘤坏死因子(依那西普,英夫利昔单抗,阿达木单抗)和195种合成dmard联合其他生物制剂(阿巴接受普,利妥昔单抗和托珠单抗)。评估结核的发生情况和药物暴露时间,并进行结核筛查。统计分析:非配对t检验和Fisher双尾检验;p & lt;0.05.结果对照组暴露时间为981例患者-年,抗tnf组暴露时间为1744例患者-年(阿达木单抗= 676例,英夫利昔单抗= 547例,依那西普= 521例),其他生物制剂组暴露时间为336例患者-年。结核病的发病率在对照组为1.01/1000患者-年,在抗肿瘤坏死因子使用者中为2.87患者-年(阿达木单抗= 4.43/1000患者-年;依那西普= 1.92/1000患者-年,英夫利昔单抗= 1.82/1000患者-年)。其他生物制剂组无结核病例发生。抗肿瘤坏死因子组的平均药物暴露时间为27(11)个月。结论使用合成DMARDs和抗肿瘤坏死因子制剂的患者结核的发病率高于使用合成DMARDs和合成DMARDs和非抗肿瘤坏死因子制剂的患者,且发生时间较晚,提示在治疗期间感染,未发现筛查失败。
{"title":"Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas – BiobadaBrasil)","authors":"Claudia Leiko Yonekura ,&nbsp;Rene Donizeti Ribeiro Oliveira ,&nbsp;David C. Titton ,&nbsp;Roberto Ranza ,&nbsp;Aline Ranzolin ,&nbsp;André L. Hayata ,&nbsp;Ângela Duarte ,&nbsp;Inês G. Silveira ,&nbsp;Hellen M. da S. de Carvalho ,&nbsp;Júlio C. Bertacini de Moraes ,&nbsp;Mirhelen Mendes de Abreu ,&nbsp;Valéria Valim ,&nbsp;Washington Bianchi ,&nbsp;Claiton Viegas Brenol ,&nbsp;Ivanio A. Pereira ,&nbsp;Izaias Costa ,&nbsp;José C. Macieira ,&nbsp;José R.S. Miranda ,&nbsp;Luiz S. Guedes-Barbosa ,&nbsp;Manoel B. Bertolo ,&nbsp;Paulo Louzada-Junior","doi":"10.1016/j.rbre.2017.05.005","DOIUrl":"10.1016/j.rbre.2017.05.005","url":null,"abstract":"<div><h3>Objectives</h3><p>To assess the incidence of tuberculosis and to screen for latent tuberculosis infection among Brazilians with rheumatoid arthritis using biologics in clinical practice.</p></div><div><h3>Patients and methods</h3><p>This cohort study used data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas – BiobadaBrasil), from 01/2009 to 05/2013, encompassing 1552 treatments, including 415 with only synthetic disease-modifying anti-rheumatic drugs, 942 synthetic DMARDs combined with anti-tumor necrosis factor (etanercept, infliximab, adalimumab) and 195 synthetic DMARDs combined with other biologics (abatacept, rituximab and tocilizumab). The occurrence of tuberculosis and the drug exposure time were assessed, and screening for tuberculosis was performed. Statistical analysis: Unpaired <em>t</em>-test and Fisher's two-tailed test; <em>p</em> <!-->&lt;<!--> <!-->0.05.</p></div><div><h3>Results</h3><p>The exposure times were 981 patient-years in the controls, 1744 patient-years in the anti-TNF group (adalimumab<!--> <!-->=<!--> <!-->676, infliximab<!--> <!-->=<!--> <!-->547 and etanercept<!--> <!-->=<!--> <!-->521 patient-years) and 336 patient-years in the other biologics group. The incidence rates of tuberculosis were 1.01/1000 patient-years in the controls and 2.87 patient-years among anti-TNF users (adalimumab<!--> <!-->=<!--> <!-->4.43/1000 patient-years; etanercept<!--> <!-->=<!--> <!-->1.92/1000 patient-years and infliximab<!--> <!-->=<!--> <!-->1.82/1000 patient-years). No cases of tuberculosis occurred in the other biologics group. The mean drug exposure time until the occurrence of tuberculosis was 27(11) months for the anti-TNF group.</p></div><div><h3>Conclusions</h3><p>The incidence of tuberculosis was higher among users of synthetic DMARDs and anti-TNF than among users of synthetic DMARDs and synthetic DMARDs and non-anti-TNF biologics and also occurred later, suggesting infection during treatment and no screening failure.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 477-483"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.05.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35194682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 28
Paraneoplastic necrotizing myopathy – a case report 副肿瘤坏死性肌病1例报告
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2013.10.007
Alberto Pereira Ferraz, Fabio Freire José
{"title":"Paraneoplastic necrotizing myopathy – a case report","authors":"Alberto Pereira Ferraz,&nbsp;Fabio Freire José","doi":"10.1016/j.rbre.2013.10.007","DOIUrl":"10.1016/j.rbre.2013.10.007","url":null,"abstract":"","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 1","pages":"Pages 82-84"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2013.10.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55047043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Idiopathic musculoskeletal pain in Indian children–Prevalence and impact on daily routine 印度儿童的特发性肌肉骨骼疼痛-患病率和对日常生活的影响
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2015.07.015
Ganesh Kumar, Amieleena Chhabra, Vivek Dewan, Tribhuvan Pal Yadav

Objectives

To study the prevalence of idiopathic musculoskeletal pain (IMSP) in school going children and its impact on daily life.

Methods

One thousand eighteen apparently healthy school children aged 5–16 years were assessed and analysed for IMSP and its associated problems. Standard tests for significance were applied.

Results

One hundred and sixty-five (16.2%) children mostly males (55.2%) reported IMSP. Lower limbs (52.1%) were the most common location of pain. More than 1 year of pain history was present in 15%. Thirty-seven percent children complained of discomfort during walking, 30.9%, had pain during physical exercise, 29.2% had difficulty attending lessons and 4.2% had interference in pursuing hobbies. The children were also further sub grouped into preadolescents and adolescents. There was significant difference in pain duration and duration of each pain episode in the two groups (p = 0.01). A significant number of children (21.2%) with IMSP reported school absenteeism (p < 0.001). A significant number of adolescents had history positive for contact sports (p = 0.001). Sleep disturbances were also reported to be higher in children with IMSP (29% vs. 5.7%, p = 0.001). Other associated problems in children with IMSP found were day time tiredness (51.1%), headache (47.3%) and abdominal pain (24.8%).

Conclusions

Prevalence of IMSP in school children aged 5–16 yrs was found to be 16.2% and a significant percentage of these children experience interference with daily activities including school absenteeism.

目的了解学龄期儿童特发性肌肉骨骼疼痛(IMSP)的患病率及其对日常生活的影响。方法对18000名5 ~ 16岁表面健康的学龄儿童进行IMSP及其相关问题的评估和分析。采用显著性标准检验。结果患儿165例(16.2%),以男性为主(55.2%)。下肢(52.1%)是最常见的疼痛部位。有1年以上疼痛史的占15%。37%的孩子在走路时感到不适,30.9%的孩子在体育锻炼时感到疼痛,29.2%的孩子在上课时感到困难,4.2%的孩子在追求爱好时受到干扰。这些孩子也被进一步分为青春期前和青少年。两组患者疼痛持续时间及每次疼痛发作持续时间差异有统计学意义(p = 0.01)。大量患有IMSP的儿童(21.2%)报告学校缺勤(p <0.001)。大量青少年有接触性运动史阳性(p = 0.001)。据报道,IMSP患儿的睡眠障碍也更高(29%对5.7%,p = 0.001)。其他与IMSP相关的问题包括白天疲劳(51.1%)、头痛(47.3%)和腹痛(24.8%)。结论5 ~ 16岁学龄儿童的IMSP患病率为16.2%,其中有显著比例的儿童出现日常活动受到干扰,包括旷课。
{"title":"Idiopathic musculoskeletal pain in Indian children–Prevalence and impact on daily routine","authors":"Ganesh Kumar,&nbsp;Amieleena Chhabra,&nbsp;Vivek Dewan,&nbsp;Tribhuvan Pal Yadav","doi":"10.1016/j.rbre.2015.07.015","DOIUrl":"10.1016/j.rbre.2015.07.015","url":null,"abstract":"<div><h3>Objectives</h3><p>To study the prevalence of idiopathic musculoskeletal pain (IMSP) in school going children and its impact on daily life.</p></div><div><h3>Methods</h3><p>One thousand eighteen apparently healthy school children aged 5–16 years were assessed and analysed for IMSP and its associated problems. Standard tests for significance were applied.</p></div><div><h3>Results</h3><p>One hundred and sixty-five (16.2%) children mostly males (55.2%) reported IMSP. Lower limbs (52.1%) were the most common location of pain. More than 1 year of pain history was present in 15%. Thirty-seven percent children complained of discomfort during walking, 30.9%, had pain during physical exercise, 29.2% had difficulty attending lessons and 4.2% had interference in pursuing hobbies. The children were also further sub grouped into preadolescents and adolescents. There was significant difference in pain duration and duration of each pain episode in the two groups (<em>p</em> <!-->=<!--> <!-->0.01). A significant number of children (21.2%) with IMSP reported school absenteeism (<em>p</em> <!-->&lt;<!--> <!-->0.001). A significant number of adolescents had history positive for contact sports (<em>p</em> <!-->=<!--> <!-->0.001). Sleep disturbances were also reported to be higher in children with IMSP (29% vs. 5.7%, <em>p</em> <!-->=<!--> <!-->0.001). Other associated problems in children with IMSP found were day time tiredness (51.1%), headache (47.3%) and abdominal pain (24.8%).</p></div><div><h3>Conclusions</h3><p>Prevalence of IMSP in school children aged 5–16 yrs was found to be 16.2% and a significant percentage of these children experience interference with daily activities including school absenteeism.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 1","pages":"Pages 8-14"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2015.07.015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55048190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
New guidelines for the diagnosis of fibromyalgia 纤维肌痛诊断新指南
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2017.07.002
Roberto E. Heymann , Eduardo S. Paiva , José Eduardo Martinez , Milton Helfenstein Jr. , Marcelo C. Rezende , Jose Roberto Provenza , Aline Ranzolin , Marcos Renato de Assis , Daniel P. Feldman , Luiz Severiano Ribeiro , Eduardo J.R. Souza

Objective

To establish guidelines based on scientific evidence for the diagnosis of fibromyalgia.

Material and methods

Evidence collection was performed based on 9 questions regarding the diagnosis of fibromyalgia, structured using the Patient, Intervention or Indicator, Comparison and Outcome (P.I.C.O.), with searches in the main, primary databases of scientific information. After defining the potential studies to support the recommendations, they were graded according to evidence and degree of recommendation.

目的建立基于科学证据的纤维肌痛诊断指南。材料和方法根据9个关于纤维肌痛诊断的问题进行证据收集,使用患者、干预措施或指标、比较和结果(P.I.C.O.)进行结构化,并在主要的、主要的科学信息数据库中进行检索。在确定了支持这些建议的潜在研究后,根据证据和推荐程度对它们进行了分级。
{"title":"New guidelines for the diagnosis of fibromyalgia","authors":"Roberto E. Heymann ,&nbsp;Eduardo S. Paiva ,&nbsp;José Eduardo Martinez ,&nbsp;Milton Helfenstein Jr. ,&nbsp;Marcelo C. Rezende ,&nbsp;Jose Roberto Provenza ,&nbsp;Aline Ranzolin ,&nbsp;Marcos Renato de Assis ,&nbsp;Daniel P. Feldman ,&nbsp;Luiz Severiano Ribeiro ,&nbsp;Eduardo J.R. Souza","doi":"10.1016/j.rbre.2017.07.002","DOIUrl":"10.1016/j.rbre.2017.07.002","url":null,"abstract":"<div><h3>Objective</h3><p>To establish guidelines based on scientific evidence for the diagnosis of fibromyalgia.</p></div><div><h3>Material and methods</h3><p>Evidence collection was performed based on 9 questions regarding the diagnosis of fibromyalgia, structured using the Patient, Intervention or Indicator, Comparison and Outcome (P.I.C.O.), with searches in the main, primary databases of scientific information. After defining the potential studies to support the recommendations, they were graded according to evidence and degree of recommendation.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 467-476"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.07.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35260101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of chikungunya fever. Part 2 – Treatment 巴西风湿病学会关于基孔肯雅热诊断和治疗的建议。第2部-处理
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2017.06.004
Claudia Diniz Lopes Marques , Angela Luzia Branco Pinto Duarte , Aline Ranzolin , Andrea Tavares Dantas , Nara Gualberto Cavalcanti , Rafaela Silva Guimarães Gonçalves , Laurindo Ferreira da Rocha Junior , Lilian David de Azevedo Valadares , Ana Karla Guedes de Melo , Eutilia Andrade Medeiros Freire , Roberto Teixeira , Francisco Alves Bezerra Neto , Marta Maria das Chagas Medeiros , Jozélio Freire de Carvalho , Mario Sergio F. Santos , Regina Adalva de L. Couto Océa , Roger A. Levy , Carlos Augusto Ferreira de Andrade , Geraldo da Rocha Castelar Pinheiro , Mirhelen Mendes Abreu , Georges Christopoulos

Chikungunya fever has become an important public health problem in countries where epidemics occur because half of the cases progress to chronic, persistent and debilitating arthritis. Literature data on specific therapies at the various phases of arthropathy caused by chikungunya virus (CHIKV) infection are limited, lacking quality randomized trials assessing the efficacies of different therapies. There are a few studies on the treatment of musculoskeletal manifestations of chikungunya fever, but these studies have important methodological limitations. The data currently available preclude conclusions favorable or contrary to specific therapies, or an adequate comparison between the different drugs used.

The objective of this study was to develop recommendations for the treatment of chikungunya fever in Brazil. A literature review was performed via evidence-based selection of articles in the databases Medline, SciELO, PubMed and Embase and conference proceedings abstracts, in addition to expert opinions to support decision-making in defining recommendations. The Delphi method was used to define the degrees of agreement in 2 face-to-face meetings and several online voting rounds. This study is part 2 of the Recommendations of the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia – SBR) for the Diagnosis and Treatment of chikungunya fever and specifically addresses treatment.

基孔肯雅热在发生流行病的国家已成为一个重要的公共卫生问题,因为半数病例发展为慢性、持续性和使人衰弱的关节炎。关于基孔肯雅病毒(CHIKV)感染引起的关节病不同阶段特异性治疗的文献资料有限,缺乏评估不同治疗效果的高质量随机试验。有一些关于治疗基孔肯雅热肌肉骨骼表现的研究,但这些研究在方法学上有重要的局限性。目前可获得的数据排除了支持或反对特定治疗的结论,或不同药物之间的充分比较。这项研究的目的是为巴西基孔肯雅热的治疗提出建议。文献综述是通过基于证据的选择Medline、SciELO、PubMed和Embase数据库中的文章和会议论文集摘要,以及专家意见来支持确定建议的决策。采用德尔菲法确定了2次面对面会议和几轮在线投票的一致程度。这项研究是巴西风湿病学会(Sociedade Brasileira de Reumatologia - SBR)关于基孔肯雅热诊断和治疗建议的第二部分,具体涉及治疗。
{"title":"Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of chikungunya fever. Part 2 – Treatment","authors":"Claudia Diniz Lopes Marques ,&nbsp;Angela Luzia Branco Pinto Duarte ,&nbsp;Aline Ranzolin ,&nbsp;Andrea Tavares Dantas ,&nbsp;Nara Gualberto Cavalcanti ,&nbsp;Rafaela Silva Guimarães Gonçalves ,&nbsp;Laurindo Ferreira da Rocha Junior ,&nbsp;Lilian David de Azevedo Valadares ,&nbsp;Ana Karla Guedes de Melo ,&nbsp;Eutilia Andrade Medeiros Freire ,&nbsp;Roberto Teixeira ,&nbsp;Francisco Alves Bezerra Neto ,&nbsp;Marta Maria das Chagas Medeiros ,&nbsp;Jozélio Freire de Carvalho ,&nbsp;Mario Sergio F. Santos ,&nbsp;Regina Adalva de L. Couto Océa ,&nbsp;Roger A. Levy ,&nbsp;Carlos Augusto Ferreira de Andrade ,&nbsp;Geraldo da Rocha Castelar Pinheiro ,&nbsp;Mirhelen Mendes Abreu ,&nbsp;Georges Christopoulos","doi":"10.1016/j.rbre.2017.06.004","DOIUrl":"10.1016/j.rbre.2017.06.004","url":null,"abstract":"<div><p>Chikungunya fever has become an important public health problem in countries where epidemics occur because half of the cases progress to chronic, persistent and debilitating arthritis. Literature data on specific therapies at the various phases of arthropathy caused by chikungunya virus (CHIKV) infection are limited, lacking quality randomized trials assessing the efficacies of different therapies. There are a few studies on the treatment of musculoskeletal manifestations of chikungunya fever, but these studies have important methodological limitations. The data currently available preclude conclusions favorable or contrary to specific therapies, or an adequate comparison between the different drugs used.</p><p>The objective of this study was to develop recommendations for the treatment of chikungunya fever in Brazil. A literature review was performed <em>via</em> evidence-based selection of articles in the databases Medline, SciELO, PubMed and Embase and conference proceedings abstracts, in addition to expert opinions to support decision-making in defining recommendations. The Delphi method was used to define the degrees of agreement in 2 face-to-face meetings and several online voting rounds. This study is part 2 of the Recommendations of the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia – SBR) for the Diagnosis and Treatment of chikungunya fever and specifically addresses treatment.</p></div>","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 438-451"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.06.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35195217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
Foundations, facts, photos and Facebook 基础,事实,照片和Facebook
Pub Date : 2017-01-01 DOI: 10.1016/j.rbre.2017.07.005
Marcos Renato de Assis, Francisco Airton Castro Rocha, Luís Eduardo Coelho Andrade, Roger Abramino Levy, Hilton Seda
{"title":"Foundations, facts, photos and Facebook","authors":"Marcos Renato de Assis,&nbsp;Francisco Airton Castro Rocha,&nbsp;Luís Eduardo Coelho Andrade,&nbsp;Roger Abramino Levy,&nbsp;Hilton Seda","doi":"10.1016/j.rbre.2017.07.005","DOIUrl":"10.1016/j.rbre.2017.07.005","url":null,"abstract":"","PeriodicalId":101096,"journal":{"name":"Revista Brasileira de Reumatologia (English Edition)","volume":"57 ","pages":"Pages 414-420"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rbre.2017.07.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35410151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista Brasileira de Reumatologia (English Edition)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1